National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Bladder Cancer. These NCCN Guidelines® are currently available as Version 2.2017. 

  • Principles of Systemic Therapy
    • Subsequent systemic therapy for locally advanced or metastatic disease
      • “Nivolumab” was added as a standard regimen option with a category 2A designation for
        • Bladder cancer
        • Upper GU tract tumors: Renal pelvis
        • Upper GU tract tumors: Urothelial carcinoma of the ureter
        • Urothelial carcinoma of the prostate
        • Primary carcinoma of the urethra (urothelial carcinomas only)

*For your reference, the previous update (Version 1.2017) to the NCCN Guidelines for Bladder Cancer, published on December 21, 2016, is available at the following link:


For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Access information on permissions and licensing of NCCN Content